You are here: Industry Insights > OPHTHALMOLOGY

News List

Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics PharmaSources.com
March 08, 2022
Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company...
American Academy of Ophthalmology Applauds UnitedHealthcare for Clarifying Drug Policy on Ophthalmic Avastin Alternatives firstwordpharma
August 18, 2021
The Academy commends UnitedHealthcare (UHC) for acting quickly to clarify its policy regarding the use of two biosimilars untested for ophthalmic/intravitreal use as alternatives to the sight-saving drug Avastin. UHC removed the drugs, Mvasi and Zirabev.
Novartis signs AI ophthalmology pact with RetinAI pharmatimes
December 10, 2020
Novartis has signed a multi-year collaboration agreement with RetinAI to utilise the latter’s IT solutions and artificial intelligence (AI) tools to support multiple projects in ophthalmology and digital health.
Digital Health: Clinical Study Published in “Ophthalmology” Demonstrates Implandata’s EYEMATE System Benefits Glaucoma Patients b3cnewswire
July 28, 2020
People suffering from glaucoma got bad news and good news from a clinical study published in the journal Ophthalmology (1) this month. Bad news: Clinical data prove, the current standard practice (applanation tonometry) for measuring IntraOcular Pressure
Aequus, Medicom Healthcare to Jointly Advance Ophthalmology Products into the US americanpharmaceuticalreview
December 18, 2019
Aequus announced the signing of a term sheet to co-commercialize a portfolio of products in the US with Medicom Healthcare ...
Biogen Completes $800M Nightstar Acquisition contractpharma
June 10, 2019
Gains two mid- to late-stage clinical assets and preclinical programs in ophthalmology.
Biogen acquisition boosts its ophthalmology pipeline cphi-online
March 07, 2019
Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.
Ocular Therapeutix crosses the finish line with eye treatment fiercepharma
December 06, 2018
After twice being sidelined by manufacturing-related CRLs, Ocular Therapeutix got FDA approval on Monday for its first eye drug.
Ophthotech adds to pipeline again as climb back continuesipeline again as climb back continues fiercebiotech
November 02, 2018
Ophthotech has signed two deals to bulk up its drug and gene therapy pipeline, following the demise of its lead wet age-related macular degeneration (AMD) candidate last year.
Apellis sets up another phase 3 program for lead drug APL-2 fiercebiotech
August 28, 2017
Trials in dry age-related macular degeneration expand Apellis Pharmaceuticals' focus beyond rare diseases.

Previous page 1 2 Next page